期刊文献+

吉非替尼一线治疗晚期非小细胞肺癌 被引量:5

下载PDF
导出
摘要 目的探讨吉非替尼一线治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法晚期NSCLC患者28例,一线应用吉非替尼250mg/d,午餐后顿服,直至患者出现肿瘤进展或不能耐受药物毒性而终止。结果28例均可评价疗效,完全缓解1例(3.6%),部分缓解11例(39.3%),疾病稳定7例(25.0%),疾病进展9例(32.1%),客观有效率为42.9%(12/28),疾病控制率为67.9%(19/28)。中位生存期为15.5个月,1年生存率为64.3%(18/28)。单因素分析显示女性、腺癌与客观有效率、疾病控制率、中位生存期明显相关(P〈0.05),年龄、手术、PS评分、吸烟史与客观有效率、疾病控制率、中位生存期无明显相关性(P〉0.05)。毒副反应:痤疮样皮疹、皮肤瘙痒、皮肤干燥21例,腹泻9例,恶心、呕吐3例,均为1、2级毒副反应,没有出现间质性肺炎。结论吉非替尼一线治疗晚期NSCLC疗效好,耐受性良好。
出处 《中国医师进修杂志(内科版)》 2009年第3期48-50,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献7

  • 1Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 2003, 21 (14) : 2787-2799.
  • 2徐建明,李月敏,刘晓晴,张扬,韩宇,杨武威,宋三泰.吉非替尼治疗晚期非小细胞肺癌[J].中华肿瘤杂志,2007,29(1):66-69. 被引量:18
  • 3Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol, 2006,1 (7) : 684-691.
  • 4Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol, 2003,21 ( 12 ) : 2237-2246.
  • 5Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 2004,22(6): 1103-1109.
  • 6王岩,徐建明,宋三泰.表皮生长因子受体靶向药物作用机制与相关标志物的研究现状[J].中华肿瘤杂志,2005,27(9):573-576. 被引量:33
  • 7Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science, 2004,304(5676): 1497-1500.

二级参考文献37

  • 1王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 2王岩,徐建明,宋三泰.表皮生长因子受体靶向药物作用机制与相关标志物的研究现状[J].中华肿瘤杂志,2005,27(9):573-576. 被引量:33
  • 3Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 2003, 21:2787-2799.
  • 4Fukuoka M, Yano S, Giaccone G, et al. A multi-institutional randomized phase II trial of ZD1839 ('Iressa') for previously treated patients with advanced non-small cell lung cancer (the IDEAL 1 trial). J Clin Oncol, 2003, 21:2237-2246.
  • 5Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) . Proc Am Soc Clin Oncol, 2002, 21:292a.
  • 6Perez-Soler R, Chanchoua A, Huberman M, et al. Finals results of a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy (abstract P-611). Lung Cancer, 2003, 41:S246.
  • 7Giaccone G, Johnson D, Scagliotti GV, et al. Results of a multivariate analysis of prognostic factors for overall survival of patients with advanced non-small cell lung cancer treated with gefitinib ('Iressa', ZD1839) in combination with platinum-based chemotherapy in two large phase III trials (INTACT 1 and 2). Pro Am Soc Clin Oncol, 2003, 22:626a.
  • 8Perez-Soler R. The role of erlotinib (Tarceva, OSI-774) in the treatment of non-small cell lung cancer. Clin Cancer Res, 2004, 10:4238s-4240s.
  • 9Kelly K, Hanna N, Rosenberg A, et al. Multicentered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol, 2003, 22:644.
  • 10Robert F, Blumenschein K, Dicke T, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer(NSCLC). Proc Am Soc Clin Oncol, 2003, 22:643.

共引文献47

同被引文献47

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部